First-in-human data for potential first-in-class anti-CEACAM5 ADC with topoisomerase 1 inhibitor payload, M9140, in treatment of metastatic colorectal cancer to be featured in oral presentation
MAINZ, Germany, May 21, 2024 - BioNTech SE(Nasdaq: BNTX, "BioNTech" or "the Company") will present clinical trial data for selected programs from the Company's diversified immuno-oncology pipeline at the
THOUSAND OAKS - Amgen today announced the presentation of new data from the CodeBreaK clinical trial program, the most comprehensive global development program in patients with KRAS G12C-mutated. | June 5, 2023
All dose levels of Radspherin were well tolerated with a maximum dose level toxicity not reached in the RAD-18-002 study. Radspherin is currently being evaluated in two ongoing Phase 1 trials for